Advertisement
GMED vs TNDM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMED is a Hold and TNDM is a Hold.
GMED's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GMED turned positive on September 25, 2026. Looking at past instances where GMED's MACD turned positive, the stock continued to rise in 38 of 51 cases over the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GMED's RSI Oscillator exited the oversold zone, 16 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on GMED as a result. In 64 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 198 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
GMED moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
GMED broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GMED entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.160) is normal, around the industry mean (2.949). P/E Ratio (19.322) is within average values for comparable stocks, (2.438). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
TNDM's Indicator enters downward trend
The Aroon Indicator for TNDM entered a downward trend on October 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 229 similar instances where the Aroon Indicator formed such a pattern. In 205 of the 229 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNDM as a result. In 66 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The 10-day moving average for TNDM crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
The 50-day moving average for TNDM moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNDM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TNDM's RSI Indicator exited the oversold zone, 39 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where TNDM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TNDM just turned positive on October 02, 2026. Looking at past instances where TNDM's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNDM advanced for three days, in 213 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. TNDM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.666) is normal, around the industry mean (2.949). P/E Ratio (-18.044) is within average values for comparable stocks, (2.438). Projected Growth (PEG Ratio) (9.850) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (1.150) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNDM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
GMED | TNDM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 65 | 98 | |
PRICE GROWTH RATING 1..100 | 50 | 61 | |
P/E GROWTH RATING 1..100 | 60 | 37 | |
SEASONALITY SCORE 1..100 | 75 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GMED's Valuation (79) in the Medical Specialties industry is in the same range as TNDM (92). This means that GMED’s stock grew similarly to TNDM’s over the last 12 months.
GMED's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as TNDM (100). This means that GMED’s stock grew similarly to TNDM’s over the last 12 months.
GMED's SMR Rating (65) in the Medical Specialties industry is somewhat better than the same rating for TNDM (98). This means that GMED’s stock grew somewhat faster than TNDM’s over the last 12 months.
GMED's Price Growth Rating (50) in the Medical Specialties industry is in the same range as TNDM (61). This means that GMED’s stock grew similarly to TNDM’s over the last 12 months.
TNDM's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as GMED (60). This means that TNDM’s stock grew similarly to GMED’s over the last 12 months.
| GMED | TNDM | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 70% | 3 days ago 83% |
| Stochastic ODDS (%) | 3 days ago 66% | 3 days ago 80% |
| Momentum ODDS (%) | 3 days ago 74% | 3 days ago 88% |
| MACD ODDS (%) | 3 days ago 75% | 3 days ago 74% |
| TrendWeek ODDS (%) | 3 days ago 65% | 3 days ago 77% |
| TrendMonth ODDS (%) | 3 days ago 61% | 3 days ago 86% |
| Advances ODDS (%) | 6 days ago 64% | 6 days ago 79% |
| Declines ODDS (%) | 11 days ago 58% | 11 days ago 86% |
| BollingerBands ODDS (%) | 3 days ago 74% | N/A |
| Aroon ODDS (%) | 3 days ago 62% | 3 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMED’s FA Score shows that 0 FA rating(s) are green while TNDM’s FA Score has 0 green FA rating(s).
- GMED’s FA Score: 0 green, 5 red.
- TNDM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMED’s TA Score shows that 4 TA indicator(s) are bullish while TNDM’s TA Score has 4 bullish TA indicator(s).
- GMED’s TA Score: 4 bullish, 5 bearish.
- TNDM’s TA Score: 4 bullish, 5 bearish.
Price Growth
GMED (@Medical/Nursing Services) experienced а +2.76% price change this week, while TNDM (@Medical/Nursing Services) price change was +0.81% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -6.10%. For the same industry, the average monthly price growth was -8.07%, and the average quarterly price growth was -16.10%.
Reported Earning Dates
GMED is expected to report earnings on Nov 05, 2026.
TNDM is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical/Nursing Services (-6.10% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
GMED and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMED has been loosely correlated with TMCI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then TMCI could also see price increases.
| Ticker / NAME | Correlation To GMED | 1D Price Change % | ||
|---|---|---|---|---|
| GMED | 100% | -2.70% | ||
| TMCI - GMED | 46% Loosely correlated | -6.07% | ||
| TNDM - GMED | 46% Loosely correlated | -1.69% | ||
| SYK - GMED | 44% Loosely correlated | +0.49% | ||
| MDT - GMED | 44% Loosely correlated | -0.73% | ||
| STE - GMED | 43% Loosely correlated | -0.74% | ||
More | ||||
TNDM and
Correlation & Price change
A.I.dvisor indicates that over the last year, TNDM has been loosely correlated with TFX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if TNDM jumps, then TFX could also see price increases.
| Ticker / NAME | Correlation To TNDM | 1D Price Change % | ||
|---|---|---|---|---|
| TNDM | 100% | -1.69% | ||
| TFX - TNDM | 45% Loosely correlated | +1.72% | ||
| GMED - TNDM | 44% Loosely correlated | -2.70% | ||
| SHC - TNDM | 40% Loosely correlated | -1.00% | ||
| AZTA - TNDM | 39% Loosely correlated | -6.65% | ||
| A - TNDM | 38% Loosely correlated | -1.47% | ||
More | ||||